CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 124 enrolled
Drug / intervention
Lidocaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05153785
NCT05153785Phase 3Completed

Intravenous Lidocaine for Postoperative Recovery in Liver Surgery, a Randomized Double Blinded Placebo-controlled Study

Lund University Hospital·interventional·Posted Dec 10, 2021·Updated Jan 15, 2026

In Brief

A Phase 3 clinical trial evaluating Lidocaine and Normal saline for Liver Metastases and 3 related conditions. Completed, enrolled 124 participants across 1 site.

Detailed Summary

This is a randomized double blinded placebo-controlled study, conducted in Lund, Sweden. Patients will be randomized in two groups, with a ratio of 1:1. The experimental arm will receive intravenous Lidocaine perioperatively, and the Control arm will receive placebo, i.e. normal Saline. Postoperative both arms will get routine pain Control with PCA, Patient Controlled Analgesia with an intravenous Oxycodone-infusion. Outcome-measures will include patients pain intensity scoring, and opioid consumption.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedDec 10, 2021
Enrollment StartNov 15, 2021
Primary CompletionJun 12, 2025
Study CompletionDec 6, 2025
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 4.6 years ago

Interventions

Lidocainedrug

Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery

Normal salinedrug

Placebo